8-K: Alkermes Settles LYBALVI Patent Dispute with Teva

Alkermes plc has entered into a settlement and license agreement with Teva Pharmaceuticals, Inc. to resolve a patent infringement lawsuit concerning LYBALVI.

Summary

• Alkermes plc, through its subsidiaries Alkermes, Inc. and Alkermes Pharma Ireland Limited, has reached a Confidential Settlement and License Agreement with Teva Pharmaceuticals, Inc.
• This agreement resolves a patent infringement lawsuit filed by Alkermes against Teva regarding all dosage strengths of Alkermes' product LYBALVI (olanzapine and samidorphan).
• The lawsuit stemmed from Teva's abbreviated new drug application (ANDA) No. 220379, which Alkermes alleged infringed on its U.S. patents for LYBALVI.
• Under the agreement, Alkermes grants Teva a non-exclusive, royalty-free license to sell its products in the U.S. starting November 12, 2039, or potentially May 12, 2040, if pediatric exclusivity is obtained, or earlier under specific conditions.
• A joint Stipulation of Dismissal with Prejudice was filed on November 9, 2026, to end the legal proceedings.
• The settlement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it resolves a significant legal dispute and secures future market exclusivity for a key product, although the terms of the license grant are important to monitor.

Positives

• Resolves a significant patent infringement lawsuit, reducing legal uncertainty and potential costs.
• Secures a defined market exclusivity period for LYBALVI in the United States, with Teva's license commencing in late 2039 or mid-2040.
• The license granted to Teva is non-exclusive and royalty-free, indicating Alkermes' strong position in the patent dispute.

Negatives

• The settlement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, which could potentially delay or alter the agreement.
• While a license is granted, it implies Teva's product will eventually enter the market, potentially impacting LYBALVI's market share post-exclusivity.

Risks

• Potential challenges or delays in the review process by the U.S. Federal Trade Commission and the U.S. Department of Justice.
• The possibility of earlier market entry for Teva's product under certain circumstances outlined in the agreement.
• Future competition from Teva's product once the licensed period begins.

Future Outlook

The settlement provides clarity on the market exclusivity for LYBALVI, with Teva's licensed market entry set for November 12, 2039, or May 12, 2040, depending on pediatric exclusivity. The agreement is subject to regulatory review.

Industry Context

StockSavvy.ai notes that resolving patent litigation is a common and critical event for pharmaceutical companies, as it directly impacts product exclusivity and future revenue streams. This settlement appears to be a strategic move by Alkermes to manage its intellectual property and secure market position for LYBALVI.

Legal Proceedings

• Patent infringement lawsuit filed by Alkermes against Teva Pharmaceuticals, Inc. in the U.S. District Court for the District of New Jersey regarding LYBALVI.
• The lawsuit alleged infringement by Teva's ANDA No. 220379 of certain Orange Book-listed U.S. Patents for LYBALVI.
• The legal proceedings have been dismissed with prejudice following the Settlement Agreement.

Stakeholder Impact

• Shareholders: The resolution of litigation reduces uncertainty and protects the long-term revenue potential of LYBALVI.
• Competitors: Teva Pharmaceuticals will have a defined path to market for its product, subject to the license terms.
• Patients: Continued access to LYBALVI is ensured, with potential future market entry of a generic or biosimilar equivalent.

Next Steps

• Awaiting review of the Settlement Agreement by the U.S. Federal Trade Commission and the U.S. Department of Justice.
• Filing the full text of the Settlement Agreement as an exhibit to the Annual Report on Form 10-K for the year ending December 31, 2026.

Key Dates

Recommendation

The settlement resolves a significant legal overhang and provides clarity on LYBALVI's market exclusivity. However, the long-term licensing terms and the eventual market entry of Teva's product warrant a cautious 'hold' until the full impact on LYBALVI's market share and profitability can be assessed post-exclusivity.

Keywords

LYBALVI, patent infringement, settlement agreement, license agreement, olanzapine, samidorphan, Teva Pharmaceuticals, ANDA